Shares of BioNTech SE were losing around 5 percent in German trading as well as around 3 percent in the pre-market activity on the Nasdaq, after the German drugmaker on Monday issued weak revenue outlook for fiscal 2025 after reporting lower fourth-quarter earnings and revenues. According to the firm, the decrease in revenues was primarily driven by lower sales of its COVID-19 vaccines...
from RTT - Top Story https://ift.tt/m5orq34
via IFTTT
from RTT - Top Story https://ift.tt/m5orq34
via IFTTT
Comments
Post a Comment